MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Mink Therapeutics' first quarter 2026 conference call and webcast. All participants will be in a listen-only mode until their question and answer session. Please note this event is being recorded, and I would now like to turn the conference over to Stephanie Perinanakar from Mink Investor Relations. Stephanie, please go ahead. Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data releases, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings, also available on our website, for a detailed description of these risks. Joining me today are Dr. Jennifer Buhl, President and Chief Executive Officer of NECARE Tutics, Dr. Teres Hammond, Head of Development, and Melissa Orleal, Principal Financial Officer. I'd like to turn the call over to Dr. Buhl to highlight our progress from this quarter. Jennifer? Thank you, Stephanie. Good morning, everyone, and thank you for joining us today. Over the past several weeks, we've presented data at four major international scientific meetings, beginning with findings in pulmonary fibrosis at the Keystone Symposium in February, followed by a presentation of our Phase II clinical data in refractory gastric cancer at AACR in April. And most recently, in fact, just earlier this week, we presented mechanistic findings at the American Society for Gene and Cell Therapy showing the context-dependent immune activity of invariant metastatic T cells in cancer and severe lung injury. We're also...